• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Albumin-Butyrylcholinesterase as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Post-hepatectomy: A Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology.

作者信息

Tadokoro Takeshi, Kobayashi Tsuyoshi

机构信息

Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Science, Hiroshima University, Hiroshima City, Hiroshima, Japan.

HiSCO: Hiroshima Surgical Study Group of Clinical Oncology, Hiroshima, Japan.

出版信息

Ann Surg Oncol. 2025 Mar;32(3):1989-1990. doi: 10.1245/s10434-024-16808-2. Epub 2025 Jan 3.

DOI:10.1245/s10434-024-16808-2
PMID:39753795
Abstract
摘要

相似文献

1
ASO Author Reflections: Albumin-Butyrylcholinesterase as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Post-hepatectomy: A Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology.ASO 作者反思：白蛋白 - 丁酰胆碱酯酶作为肝癌肝切除术后的新型预后生物标志物：与广岛临床肿瘤外科学术研究组的一项回顾性队列研究
Ann Surg Oncol. 2025 Mar;32(3):1989-1990. doi: 10.1245/s10434-024-16808-2. Epub 2025 Jan 3.
2
Albumin-Butyrylcholinesterase as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Post-hepatectomy: A Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology.白蛋白-丁酰胆碱酯酶作为肝癌肝切除术后的一种新型预后生物标志物：广岛临床肿瘤外科研究组的一项回顾性队列研究
Ann Surg Oncol. 2025 Mar;32(3):1973-1984. doi: 10.1245/s10434-024-16650-6. Epub 2024 Dec 10.
3
Prognosis of repeat hepatectomy for liver transplantable hepatocellular carcinoma recurrence after hepatectomy: a Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO).肝移植术后肝癌切除术后复发行再次肝切除术的预后：广岛临床肿瘤外科研究组（HiSCO）的回顾性队列研究。
Langenbecks Arch Surg. 2023 Aug 16;408(1):314. doi: 10.1007/s00423-023-03057-2.
4
ASO Author Reflections: Perioperative Lymphopenia Following Hepatectomy for Hepatocellular Carcinoma: A Routine Yet Overlooked Prognostic Biomarker.ASO作者反思：肝细胞癌肝切除术后围手术期淋巴细胞减少症：一种常见但被忽视的预后生物标志物。
Ann Surg Oncol. 2024 Apr;31(4):2604-2605. doi: 10.1245/s10434-023-14856-8. Epub 2024 Jan 4.
5
ASO Author Reflections: The FIBA Score-A Novel Scoring System to Predict Outcomes in Hepatocellular Carcinoma After Surgical Resection or Transarterial Chemoembolization.ASO作者反思：FIBA评分——一种预测肝细胞癌手术切除或经动脉化疗栓塞术后预后的新型评分系统。
Ann Surg Oncol. 2023 Apr;30(4):2021-2022. doi: 10.1245/s10434-022-12959-2. Epub 2022 Dec 24.
6
ASO Author Reflections: The Prognostic Value of Preoperative Serum Markers and Risk Classification of Patients With Hepatocellular Carcinoma.ASO作者反思：术前血清标志物对肝细胞癌患者的预后价值及风险分类
Ann Surg Oncol. 2023 May;30(5):2816-2817. doi: 10.1245/s10434-022-13063-1. Epub 2023 Feb 3.
7
ASO Author Reflections: Laparoscopic R1 Vascular Hepatectomy for Hepatocellular Carcinoma: A Step Forward.ASO作者反思：腹腔镜下R1血管性肝切除术治疗肝细胞癌：向前迈进的一步。
Ann Surg Oncol. 2021 Jul;28(7):3701-3702. doi: 10.1245/s10434-021-09635-2. Epub 2021 Feb 20.
8
ASO Author Reflections: Is Histologic Liver Inflammation a Predictor in Patients with Hepatocellular Carcinoma after Hepatectomy?ASO作者反思：组织学肝炎症是肝细胞癌患者肝切除术后的预测指标吗？
Ann Surg Oncol. 2022 Feb;29(2):903-904. doi: 10.1245/s10434-021-10712-9. Epub 2021 Aug 27.
9
ASO Author Reflections: Perspectives of Laparoscopic Hepatectomy with Venous Tumor Thrombectomy for Hepatocellular Carcinoma.ASO作者反思：肝细胞癌腹腔镜肝切除联合静脉肿瘤血栓切除术的观点
Ann Surg Oncol. 2021 Dec;28(13):8240-8241. doi: 10.1245/s10434-021-10361-y. Epub 2021 Jun 25.
10
ASO Author Reflections: Hepatectomy for Multiple Hepatocellular Carcinomas.ASO作者反思：多发性肝细胞癌的肝切除术
Ann Surg Oncol. 2022 Dec;29(13):8446-8447. doi: 10.1245/s10434-022-12507-y. Epub 2022 Sep 5.

本文引用的文献

1
Albumin-Butyrylcholinesterase as a Novel Prognostic Biomarker for Hepatocellular Carcinoma Post-hepatectomy: A Retrospective Cohort Study with the Hiroshima Surgical Study Group of Clinical Oncology.白蛋白-丁酰胆碱酯酶作为肝癌肝切除术后的一种新型预后生物标志物：广岛临床肿瘤外科研究组的一项回顾性队列研究
Ann Surg Oncol. 2025 Mar;32(3):1973-1984. doi: 10.1245/s10434-024-16650-6. Epub 2024 Dec 10.
2
Management of Hepatocellular Carcinoma: A Review.肝细胞癌的管理：综述
JAMA Surg. 2023 Apr 1;158(4):410-420. doi: 10.1001/jamasurg.2022.7989.
3
Sarcopenia, Malnutrition, and Cachexia: Adapting Definitions and Terminology of Nutritional Disorders in Older People with Cancer.
肌肉减少症、营养不良和恶病质：癌症老年患者营养障碍定义和术语的调整。
Nutrients. 2021 Feb 26;13(3):761. doi: 10.3390/nu13030761.
4
Combination of Serum Albumin and Cholinesterase Levels as Prognostic Indicator in Patients With Colorectal Cancer.血清白蛋白和胆碱酯酶水平联合作为结直肠癌患者的预后指标
Anticancer Res. 2019 Feb;39(2):1085-1090. doi: 10.21873/anticanres.13217.
5
Low serum level of cholinesterase at recurrence of pancreatic cancer is a poor prognostic factor and relates to systemic disorder and nerve plexus invasion.胰腺癌复发时血清胆碱酯酶水平低是一个不良预后因素，且与全身紊乱及神经丛侵犯有关。
Pancreas. 2008 Apr;36(3):241-8. doi: 10.1097/MPA.0b013e31815b6b2b.